DEFA14A
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ý
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
|
o |
|
Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2)) |
|
o |
|
Definitive Proxy Statement |
|
ý |
|
Definitive Additional Materials |
|
o |
|
Soliciting Material Pursuant to §240.14a-12 |
EMAGEON
INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
ý |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and
state how it was determined): |
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials: |
|
|
|
|
|
o |
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the form or schedule and the
date of its filing. |
|
(1) |
|
Amount previously paid: |
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
|
|
On November 26,
2008, Emageon, Inc. distributed the following document to its sales
and customer relations directors. |
RSNA Talking Points about HSS
HSS Announces Definitive Agreement for Acquisition of Emageon
Talking Points for Emageon Sales and Customer Relations Directors
KEY MESSAGES:
|
|
|
HSS and Emageon have signed a definitive merger agreement to create a dynamic source of
healthcare IT innovation. |
|
|
|
|
An anticipated benefit will be to accelerate the speed to market of a better next
generation of Picture Archiving and Communications Systems (PACS) just as the replacement
cycle is beginning in 2009-2010. |
|
|
|
|
Customers will experience little to no immediate change to the way in which they do
business with either company. |
|
|
|
|
The deal is an all cash transaction valued at approximately $62 million, to be financed
by HSS majority shareholder, Stanford International Bank, a member of the Stanford
Financial Group. |
|
|
|
|
The transaction is expected to close December 19, 2008. |
1. What led Emageon to pursue this deal?
As part of its recent proxy settlement with Oliver Press Partners, Emageon agreed to empower a
special committee of the Board, to be chaired by an OPP Director, to explore strategic alternatives
for the company. The committee was formed immediately after the proxy settlement and the committee
hired bankers in early July. Jefferies, the banker selected by the committee, led a comprehensive
sales process that culminated in the transaction with HSS.
2. What are the benefits to Emageon?
Our expectation is that, over time, the acquisition will result in a larger healthcare information
technology company with new products and significant cross-selling opportunities. We believe that
the acquisition will allow us to deliver powerful technological solutions that have a significant
impact on the bottom lines of our customers by enhancing their patients quality of life.
3. Who is Health Systems Solutions?
HSS is a technology and services company dedicated to bringing innovation to the healthcare
industry. Its objective is to leverage current and next-generation technologies to offer
value-added products and services which will generate improved clinical, operational and financial
outcomes for its clients. The HSS portfolio of products and services extends across many segments
of healthcare including home healthcare, medical staffing, acute and post-acute facilities, and
telehealth/telemedicine, grouped into three segments: technology solutions, software and
consulting.
Health Systems Solutions, Inc. is a publicly traded company listed on the Over the Counter Bulletin
Board under the symbol HSSO. For more information visit www.healthsystemssolutions.com.
4. How does home healthcare focus fit into the PACS strategy?
Both are solutions that need constant investment to remain driven by the latest technology
standards. This ensures that the best solutions are available to meet both todays and tomorrows
healthcare challenges. HSS is not exclusively focused on any one segment of the healthcare
industry. HSS views its company as a technology organization that markets and develops cutting-edge
technology solutions to customer needs, regardless of the clinical setting.
5. Who is the Stanford Financial Group?
Stanford Financial Group is a privately held global network of independent, affiliated financial
services companies. Stanfords core businesses are private wealth management and investment banking
for institutions and emerging growth companies.
The Stanford Financial Group of companies provides private and institutional investors with global
expertise in asset allocation strategies, investment advisory services, award-winning policy and
equity research, international private banking and trust administration, commercial banking,
investment banking, merchant banking, institutional sales and trading, real estate investment and
insurance. Stanford has over $50 billion in assets under management or advisement.
Securities products and services are offered in the United States by Stanford Group Company, member
FINRA/SIPC. Stanford Financial Group is not a legal entity, but a registered trademark that
encompasses the global network of independent, but affiliated, privately held and wholly owned
entities. More information on the company can be found at www.stanfordfinancial.com.
6. What is Stanford Financial Groups relation with HSS?
Stanford International Bank, Ltd., beneficially owns approximately 86% of the outstanding common
stock of HSS. Stanford International Bank is a member of the Stanford Financial Group.
7. How much do you plan to invest in R&D going forward?
Emageon is currently spending more on its next-generation PACS product than it has ever spent on a
previous product development. Going forward, HSS intends to build on the successes Emageon has
achieved by ensuring an aggressively entrepreneurial environment that encourages and rewards
innovation. As the product is a direct function of development work, we plan to commit the
necessary resources, while keeping a close eye on operating efficiencies.
8. What will happen to the Emageon Birmingham and Hartland locations?
All existing Emageon locations will continue to operate as they have until now. Ultimately, after
the completion of the acquisition, decisions will be driven by how customers will be best served
with the minimizing or eliminating of any potential disruptions in the transition.
9. What does HSS management know about the PACS space?
HSS CEO, Stan Vashovsky, launched and built two service companies in the imaging technology space.
The HSS development team which has worked under Mr. Vashovsky for several years has expertise
in imaging technology and the leadership team that we continue to assemble will bring unrivaled
subject-matter expertise to our organization, as well.
10. What is HSS strategy and how does Emageon fit in?
HSS is a technology company that is committed to bringing outcome-improving, cost-effective
innovation to the healthcare industry. Emageon is a technology company that has a proud history of
industry-leading products and is a natural fit for both the strategy and culture of HSS.
11. Who will run the business?
After the closing, Emageon management will continue to operate the business as before.
12. As a customer, who will I be dealing with until the merger?
Until the deal is closed, it is business as usual with Emageon. Once it is closed, the intent is to
have that relationship continue for our customers such that they see the merger as a transparent
process that only enhances the quality and effectiveness of their business relationship.
13. If theres a product support problem, who do I contact?
If you have a question or concern with an Emageon product or service, you will contact the same
person(s) as you would have prior to this announcement.
Additional Information About The Transaction
In connection with the proposed merger, Emageon filed a definitive proxy statement with the SEC on
November 14, 2008. Stockholders of Emageon are encouraged to read the proxy statement (and any
other relevant documents that Emageon files with the SEC), because it contains important
information about Emageon and the proposed transaction. Stockholders may obtain a free copy of the
proxy statement and other documents filed by Emageon at the Securities and Exchange Commissions
Web site at http://www.sec.gov. Copies of the proxy statement and such other documents can also be
obtained, without charge, by directing a request to:
Emageon Inc.
1200 Corporate Drive, Suite 200
Birmingham, Alabama 35242
Attn.: Matt Geller
Telephone Number: (205) 980-9222
Stockholders are urged to read the proxy statement and all other relevant materials before making
any voting or investment decision with respect to the proposed transaction.
Emageon and its directors and executive officers and other members of management and employees may
be deemed to be participants in the solicitation of proxies in connection with the proposed merger.
Information concerning the interests of these participants in the solicitation is set forth in
Emageons annual report on Form 10-K for its fiscal year ended December 31, 2007 filed with the SEC
on March 17, 2008 and amended on April 29, 2008, in its proxy statement for its 2008 annual meeting
of shareholders filed on June 23, 2008, and in the proxy statement relating to the merger.
Forward-Looking Statements
Information contained in this document, other than historical information, may be considered
forward-looking in nature. Forward-looking statements in this document include our expectations
regarding the future offerings, integration and operation of the combined HSS and Emageon entities.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those anticipated, estimated or expected.
Emageon disclaims any intention or obligation to update or revise any forward-looking statement
whether as a result of new information, future events or otherwise.